Business
DECN Fills in the Gaps, Adds to Knowledge Base for its GenViro(TM) Coronavirus (Covid19) Multi-Dimensional Diagnostic Methodology Announced March 2
DECN Fills in the Gaps, Adds to Knowledge Base for its GenViro(TM) Coronavirus (Covid19) Multi-Dimensional Diagnostic Methodology Announced March 2.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"GenViroTM Anticipated to be Commercial Ready in Summer 2020, Advanced Development Taking Place at "Ground Zero" in Daegu, Korea, Cost Per Screen Set at $4.95, Unique Reporting Method to be UsedLOS ANGELES, CA / ACCESSWIRE / March 4, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug") test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate Precis products manufactured for International markets.On March 3, 2020, in a break-through discussed then for the first time, DECN announced the introduction of its new screening methodology for the Coronavirus (covid19). This innovative, precise and cost effective product is timely, simple to use, and most importantly will be commercial ready in the late summer of 2020. This is the second of a planned three discussions covering the revolutionary DECN GenViro screening diagnostic for the Coronavirus (covid19) and other infectious disease states. Keith Berman, CEO of DECN commented, "GenViro for the Coronavirus (covid19) began as an outgrowth of our GenUltimate TBG product line. What makes the testing for the Coronavirus possible, and the GenUltimate TBG special, is the company's Impedance measurement technology.https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/fullWhile infectious disease testing and management has not previously been a part of our business model, we seized on this "do good" opportunity because our "Gen" line of products are and have been manufactured since 2016 in what is ground zero for Coronavirus (covid19) in Daegu, Korea. The company will have available samples of the blood of those previously infected available for testing as the company quickly converts its GenUltimate TBG methods and Precise meter, into a precise infectious disease testing device for the screening for Coronavirus."In addition, the company has also just introduced its GenExpidient! Universal Translator for bio-sensor devices of different m...